Actavis Forecasts 2012 Sales in Excess of €2 Billion

19.10.2012 - Actavis, the Swiss generic drugmaker that Watson Pharmaceuticals is taking over, said revenue would rise to more than €2 billion ($2.6 billion) this year, driven by patent expiries...